Table 1. Baseline patient characteristics.
| 0 weeks (N=52a) | 24 weeks (N=54b) | 52 weeks (N=53c) | All (N=159) | |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | |
| Male | 20 (38%) | 28 (53%) | 31 (58%) | 79 (50%) |
| Race | ||||
| Caucasian | 45 (86%) | 40 (74%) | 40 (75%) | 125 (79%) |
| Asian | 3 (6%) | 4 (8%) | 3 (6%) | 10 (6%) |
| Black | 2 (4%) | 4 (8%) | 6 (11%) | 12 (8%) |
| Hispanic | 0 (0%) | 4 (8%) | 1 (2%) | 5 (3%) |
| Other | 2 (4%) | 1 (2%) | 3 (6%) | 6 (4%) |
| Alcohol/substance abuse comorbidity | 23 (44%) | 17 (31%) | 22 (42%) | 62 (39%) |
| Other psychiatric comorbidity | 9 (17%) | 15 (28%) | 17 (32%) | 41 (26%) |
| Episode type | ||||
| Manic | 43 (83%) | 45 (83%) | 43 (81%) | 131 (82%) |
| Mixed | 9 (17%) | 9 (17%) | 10 (19%) | 28 (18%) |
| Drug combination, n (%) | ||||
| Lithium+Olanzapine | 10 (19%) | 10 (19%) | 11 (20%) | 31 (19%) |
| Lithium+Risperidone | 17 (33%) | 19 (35%) | 18 (34%) | 54 (34%) |
| Epival+Olanzapine | 12 (23%) | 11 (20%) | 12 (23%) | 35 (22%) |
| Epival+Risperidone | 13 (25%) | 14 (26%) | 12 (23%) | 39 (25%) |
| Mean (s.d.) | Mean (s.d.) | Mean (s.d.) | Mean (s.d.) | |
| Age (year) | 38.96 (15.43) | 38.13 (13.59) | 36.66 (11.32) | 37.91 (13.49) |
| Weight (kg) | 71.58 (11.48) | 84.56 (23.74) | 84.42 (19.60) | 80.33 (19.90) |
| Duration of bipolar disorder (year) | 10.56 (11.70) | 10.98 (11.27) | 11.71 (10.27) | 11.08 (11.04) |
| Lithium levels (mmol/L) | 0.79 (0.19) | 0.81 (0.16) | 0.79 (0.24) | 0.80 (0.20) |
| Valproate levels (μmol/L) | 469.19 (139.68) | 484.47 (111.08) | 504.25 (113.68) | 485.47 (121.53) |
| Olanazpine dose (mg) | 10.11 (4.53) | 10.60 (5.64) | 9.57 (4.44) | 10.08 (4.82) |
| Risperidone dose (mg) | 2.08 (1.10) | 2.38 (1.41) | 2.45 (1.46) | 2.31 (1.33) |
Abbreviation: s.d., standard deviation.
a
One patient missing weight; two patients missing lithium level.
b
One patient missing age, gender, race; two patients missing lithium level.
c
One patient missing valproate level and duration of bipolar disorder.